Some patients with mild heart failure show significant, long-term benefits from cardiac-resynchronization therapy, according to the 7-year results from Boston Scientific‘s (NYSE:BSX) MADIT-CRT clinical trial presented at the American College of Cardiology’s annual meeting over the weekend.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
ACC 2014: Sapien XT bests CoreValve in small head-to-head study
UPDATED March 31, 2014, with comment from Medtronic
ACC 2014: Medtronic can skip FDA panel on positive high-risk CoreValve data
Medtronic launches cardiac arrest trial for developing nations
Terumo inks deal for Arterial Remodeling’s bioresorbable stent
Arterial Remodeling Technologies said it inked a deal with Terumo Corp. (TYO:4543) for its bioresorbable drug-eluting coronary stent that includes an exclusive buyout option.
Neovasc raises $22.5M for cardiac implants
Transcatheter Tech. touts no leakage at 6-months with Trinity TAVI
Transcatheter Technologies GmbH touted 6-month results from a pilot study of its Trinity transcatheter aortic valve implantation system, reporting no instances of valve leakage.
Volcano appeals loss to St. Jude Medical in FFR war
Boston Scientific lands E.U. approval for Rebel bare-metal stent
Medtech titan Boston Scientific (NYSE:BSX) won European regulatory approval for its Rebel bare-metal stent, a drug-free version of its Promus Premier device.
Svelte Medical raises another $5M
New Jersey-based Svelte Medical plans to accelerate regulatory efforts for its interventional cardiology products thanks to a new $5 million investment from West Health Investment Fund.
OrbusNeich launches Combo stent pivotal trial in bid for Japanese approval
OrbusNeich Medical said it launched a clinical trial in the U.S. and Japan for its Combo dual-therapy coronary stent as it gears up to apply for Shonin approval in Japan.